Extended-Release Bexagliflozin Tablets for Peak Plasma Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bexagliflozin formulations exhibit a high peak/trough ratio in plasma concentration, leading to potential adverse drug reactions due to high peak concentrations, which are difficult to predict and can lead to medication withdrawal.
Innovation Solution
Formulating bexagliflozin as an extended release tablet with gastric retention adaptations to control plasma concentration, reducing peak levels while maintaining therapeutic levels, using effervescent excipients, mucoadhesive properties, and dispersal into multiple granules to ensure absorption in the small intestine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If bexagliflozin is administered as immediate-release dosage forms, then the drug provides rapid therapeutic effect, but the plasma concentration exhibits high peak/trough ratio leading to adverse drug reactions
Solution Approach 1:
The patent segments the drug delivery process by dividing the bexagliflozin dosage into multiple granules or pellets with different release characteristics. This segmentation allows the drug to be released gradually over time rather than all at once, reducing the peak plasma concentration while maintaining therapeutic efficacy. The segmented structure enables controlled release kinetics that prevent the high Cmax associated with immediate-release formulations.
Solution Approach 2:
The patent implements periodic action through extended-release formulation that delivers bexagliflozin in a controlled, sustained manner over an extended period. This periodic release pattern maintains plasma concentrations within the therapeutic window for longer durations, avoiding the sharp peaks and troughs characteristic of immediate-release dosing. The extended release profile ensures steady drug levels without exceeding safe concentration thresholds.
2Reliability
If bexagliflozin is administered in large doses to achieve therapeutic effect, then the pharmacological effect is sufficient, but the likelihood of adverse reactions increases
Solution Approach 1:
The patent changes the release rate parameter of bexagliflozin from rapid (immediate-release) to slow and sustained (extended-release). This parameter change in release kinetics allows the same total dose to be delivered over an extended period, maintaining therapeutic efficacy while keeping instantaneous plasma concentrations below the threshold for adverse reactions. The modified release parameter transforms the dosing profile to be safer while equally effective.
Solution Approach 2:
The patent introduces an extended-release delivery system as an intermediary between the bexagliflozin drug substance and the patient's bloodstream. This intermediary control mechanism regulates the rate and pattern of drug absorption, preventing direct exposure to high peak concentrations that would cause adverse reactions. The delivery system acts as a buffer that mediates the interaction between the drug and the body, ensuring safe and effective therapy.
3Object-affected harmful factors
If bexagliflozin is formulated for extended release, then the peak plasma concentration is reduced, but the device complexity increases
Solution Approach 1:
The patent uses segmentation of bexagliflozin into multiple granules or pellets, where each granule can be a simple spherical or pellet form. This segmentation approach achieves extended-release functionality through the collective behavior of many simple units rather than requiring complex individual structures. The simplicity of each granule unit reduces manufacturing complexity while the aggregated system provides the desired extended-release profile.
Data Source
AI summary
The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.